Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12887MR)

This product GTTS-WQ12887MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12887MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10090MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ13316MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ5677MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ6672MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ13743MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ9360MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ672MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW